A new vascular regenerative therapy for myocardial ischemia using intergin-specific circulating monocytes

Research Project

Project/Area Number	24K19425
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 55030:Cardiovascular surgery-related
Research Institution	National Cardiovascular Center Research Institute
Principal Investigator	Le Thi.Hue 国立研究開発法人国立循環器病研究センター, 研究所, リサーチフェロー (80906280)
Project Period (FY)	2024-04-01 – 2027-03-31
Project Status	Granted (Fiscal Year 2024)
Budget Amount *help	¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000) Fiscal Year 2026: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2025: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2024: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	angiogenesis / monocyte / integrin / decellularized tissue / myocardial infarction
Outline of Research at the Start	In this project, I aim to develop a vascular regenerative therapy for the ischemic heart using a combination of circulating monocytes (MN) and an integrin-specific decellularized extracellular matrix (dECM)-derived injectable hydrogel. The hydrogel as a safety vascular scaffold is to promote the differentiation of circulating monocytes into endothelial cell-like cells as well as to increase cell viability after injection.